Navigation Links
ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma
Date:12/22/2011

iroPharma's intent to broaden our portfolio of development opportunities for rare and serious unmet medical needs," commented Vincent Milano, ViroPharma's president and chief executive officer. "Eosinophilic esophagitis is an emerging, rare condition that currently has no approved therapy. This disease profoundly affects the lives of these patients, causing stomach and chest pain and affecting their ability to swallow and eat normally. Over time, this disease can lead to malnutrition, significant weight loss, and potentially esophageal damage. We look forward to working with Meritage to advance the development of oral budesonide suspension toward the goal of one day providing a solution to treat this debilitating disease."

"We look forward to collaborating with ViroPharma to develop OBS to treat this serious disease," added Elaine Phillips, president and chief executive officer, Meritage. "Our goal is to ensure that this therapy is available for EoE patients and their caregivers as soon as possible."

Oral budesonide suspension was granted Orphan Drug Designation by the FDA in June of 2011 for the treatment of patients with eosinophilic esophagitis. Orphan drug designation entitles the developer to seven years of market exclusivity in the United States upon FDA approval of oral budesonide, provided that the company continues to meet certain conditions established by the FDA. Other potential advantages of Orphan Drug Designation include protocol assistance, the potential for priority review, tax credits, and other financial incentives.

Phase 2 Clinical Data (PEER Study)

A Phase 2 placebo controlled dose-ranging clinical trial in pediatric patients with EoE conducted by Meritage enrolled 82 patients with 71 completing therapy. Meritage evaluated OBS treatment by assessing histologic response (most notably the extent of esophageal eosinophilia) and clinical symptoms. Analyses of the compound primary endpoint, histologic response and r
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Today, ... a new extension to its PageCenterX ® ... software is designed to provide downtime reporting capabilities ... outages. LRS is releasing the product for general ... environment, EMR applications experience outages for a variety ...
(Date:7/31/2014)... CITY, Calif. , July 31, 2014  Genomic Health, ... company will host a conference call and webcast on Thursday, ... second quarter 2014 financial results.  The call and webcast will ... market close. Conference Call Details To access the ... Time via phone, please dial (877) 303-7208 from ...
(Date:7/31/2014)... 31, 2014 Nutrastar International Inc. (OTCQB: NUIN; ... of premium branded consumer products, including commercially cultivated Cordyceps ... today announced the signing of its first distributor for ... to Hubei Province ... China . The contract with ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... March 5 A study published by Deborah ... the Journal of Drugs in Dermatology ... resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes ... for rapid healing, less downtime and profound results. Dr. ...
... Complications Reported With Coronary DeviceDOYLESTOWN, Pa., March 4 ... in February by completing the enrollment of 30 ... clinical trial for the vProtect(TM) Luminal Shield, conducted ... Shield successfully crossed all target lesions and was ...
Cached Medicine Technology:New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation 2Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 ... H2 2014, provides an overview of the Brain ... information on the therapeutic development for Brain Cancer, ... assessment by drug target, mechanism of action (MoA), ... with latest updates, and featured news and press ...
(Date:7/31/2014)... July 31, 2014 Much of the liver,s metabolic ... body clock and UC Irvine researchers have now ... The study, published online today in Cell , ... metabolism and points the way to more focused drug ... obesity and diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren ...
(Date:7/31/2014)... The virus that causes cold sores -- herpes simplex type ... according to a new study. Researchers in Australia ... infected with the virus. This explains why some people with ... them only occasionally. The authors said the findings could lead ... when the disease was dormant, it was a truce. It ...
(Date:7/31/2014)... 31, 2014 i2i Systems announced today ... Inc. (SAS) to provide a robust patient referral ... SAS is one of the largest independent software companies ... than 40,000 patients are seen annually in its on-site ... delivering primary care, providers at the SAS HCC refer ...
(Date:7/31/2014)... Over the past five years, the ... the estimated 151 million individuals that have required some ... of Ophthalmology (AAO). According to a Consumer Reports National ... vision correction surgery, a large share of consumers have ... medical procedure was to eliminate the use of glasses ...
Breaking Medicine News(10 mins):Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 4Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... , , , ... e-Zassi.com(TM), an online decision support software system, integrated business ... has partnered with Medical Development Group (MDG), a medical device ... agreement, MDG will provide access to the e-Zassi platform to ...
... Aug. 12 Hank Oprinski, the CEO at Cap ... tour to inform corporations, chambers of commerce, golfing communities, economic clubs, universities ... , What did all the following businessmen have ... Tiger Woods) , Merv Griffin (TV Producer) , Tom Witter (Dean/Witter/Reynolds) , ...
... , , , ... today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been ... , "The technology of the Advantage VRD ... noted company Chairman, Eric P. Milledge. "The technical platform behind ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
... , , LONDON, Aug. ... optimal and efficient way and, at the same time, adhere ... pharmacovigilance tools and technologies. , , (Logo: ... Frost & Sullivan ( http://www.healthcareIT.frost.com ), World Pharmacovigilance Markets ...
... ... A GPS navigation device allows you to most accurately ... above the Earth’s surface - instantly. This multi-perspective triangulation clearly leads ... performance measurement system incorporates a number of key vital signs from ...
Cached Medicine News:Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 2Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 3Health News:September is Prostate Cancer Awareness Month 2Health News:Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 2Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 3Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 3
... MDS display system provides maximum impact for ... This unique approach to displaying frames allows ... and create appealing, flexible and eye-catching displays. ... and your patients are motivated. Removable holders. ...
A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
A pre-assembled, rectangular shadow box/wall hanging display. It have 3 adjustable shelves with tempered glass, four 50 watt halogen top lights, laminated deck, dust resistant and electrical cord wit...
Classic is proud to provide top-quality vision eyewear to physicians, health maintenance organizations (HMOs), and numerous state and federal government programs. Classic Laboratory produces over 150...
Medicine Products: